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Abstract
Bioactive components of Ganoderma lucidum has recently gained intense research attention due to their acclaimed
nutritional and medicinal properties. Thus, the terpenoid extract from the fruit bodies of G. lucidum (GT) was
evaluated for activity against Plasmodium berghei in mice in two separate experiments. In addition, the effects of
the extract on erythrocyte and hepatic lipids as well as liver HMG-CoA reductase activity before and after the
treatments were also assessed. Mice with established infection were administered 100 and 250 mg/kg/day GT alone
and in combination with chloroquine (CQ), in either case two separate controls designated: CQ (30 mg/kg
chloroquine) and INF-CTR (1 mL DMSO) were also included. Treatment was administered orally for 12 days and
parasitemia determined every three days. Percentage survival was significantly increased to 87% from 66% due to
combination of GT100 with CQ compared to GT100 alone and to 75% from 62% when GT250 was administered
with CQ compared to GT250 alone. Erythrocyte triglycerides, total cholesterol (TC), LDL and phospholipids contents
were significantly lower in GT + CQ-treated mice compared to CQ alone and INF-CTR. Similarly, hepatic TC and
phospholipid levels were significantly lower in the GT + CQ-treated mice compared to CQ alone and INF-CTR and
HMG-CoA reductase activity in the liver was significantly inhibited due to administration of GT + CQ. Data from this
study suggest that the anti-plasmodial action of GT could involve mechanisms associated with its hypolipidemic
activity. It was also demonstrated that chloroquine, when administered in combination with GT, potentiates its
curative effect in P. berghei-infected mice.
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Introduction
Malaria remains a major public health challenge affect-
ing 3.3 billion people in 106 countries and territories.
About 216 million malaria cases are reported to occur
annually 81% of which occur in the African sub-region
[1]. Out of about 438,000 deaths resulting from malaria
in 2015, an estimated 90% were traced to sub-Saharan
Africa [1]. Nigeria with about 51 million cases and
207,000 deaths contributes approximately 30% of Afri-
can annual malaria burden. According to a WHO report
about 97% of the total Nigerian population (approxi-
mately 175 million) is at risk of malaria infection [1].
The rising problem of resistance to available chemo-
therapies and problem of recrudescence of malaria after
treatment with artemisinin stress the need for new anti-
malarial agents [2]. The classical drugs quinine and arte-
misinin are both plant derivatives obtained from
Cinchona specie [3] and Artemisia annua [4] respect-
ively, suggesting that other effective drugs might be
plant-derived. Plants and fungi products have formed a
major component of foods and therapeutic agents of
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indigenous African communities for centuries. In recent
times, increased research attention has focused on phy-
tochemicals extracted from plants with traditionally
acclaimed medicinal properties in order to elucidate the
scientific basis for their observed activities and to seek
new lead compound from them which could be devel-
oped into therapeutic drugs with enhanced efficacy and
minimal side effects [5].
The rationale for the search of antimicrobial com-
pounds from fungi is that both fungi and humans share
common microbial pathogens such as Escherichia coli
and Staphylococcus aureus, therefore we can benefit
from their defense strategies against these microorgan-
isms [6]. There has been paucity of information on Afri-
can Ganoderma and majority of medicinal investigations
on Ganoderma species have been carried out on species
that have been isolated from other parts of the world.
Since species within the Ganodermataceae family all
have a common evolutionary history, it is not unlikely
that African Ganoderma may contain similar com-
pounds to those isolated elsewhere.
Ganoderma lucidum is an edible mushroom with long
history of use as a medicinal herb in Oriental countries
[7]. The extract has been investigated for its health bene-
fits in preventing cardiovascular disease, cancer, and mi-
crobial infection, and for its lipid and glucose lowering,
anti-inflammation, anti-oxidant, anti-parasite, and mul-
tiple organ protection effects [8–15]. Its long history of
usage with no attendant toxicity represents the desired
end result in the development of effective therapeutic
interventions.
In West Africa, many health claims have been made
on the effect of Ganoderma species on immune system.
Traditional medical practitioners usually consider Gano-
derma as natural immune regulator [9]. Bioactive com-
ponents of the medicinal mushroom, Ganoderma
lucidum has recently gained intense research attention
due to their acclaimed nutritional and medicinal proper-
ties. Experimental evidences revealed that the terpenoids
are the most important biologically active substances in
Ganoderma lucidum due to their varying pharmaco-
logical applications [8, 9]. Terpenoids extracted from
Ganoderma lucidum have been demonstrated to exhibit
anti-hypertensive [8], hypocholesterolemic [10, 11], he-
patoprotective [12], and cytotoxicity against numerous
cancer cell lines [13]. A recent study by Oluba et al. [15]
demonstrated the promising potential of crude chloro-
form extract of Ganoderma lucidum fruit body as an
anti-plasmodial agent.
Changes in erythrocyte lipid composition and the host
oxidant-antioxidant status are two critical associated
events involved in the pathogenesis of malaria [16]. Dur-
ing the intraerythrocytic stage of the parasite develop-
ment, about 5 to 10 merozoites are produced every 24 h.
A corresponding increase in metabolic activity with con-
comitant membrane turn-over rate is required to sustain
the growing parasite at this stage. Labaied et al. [17]
have shown that Plasmodium falciparum infection in-
duces a six-fold increase erythrocyte phospholipid con-
tent. In order to meet up with its high requirement for
phospholipids, the infected erythrocytes contain
phospholipid synthesizing enzymes [18]. Thus, potent
inhibitors of plasmodial phospholipid synthesis was pre-
viously characterized as potential target for anti-malarial
chemotherapy due to its crucial role to the parasite sur-
vival [19].
The mechanism(s) contributing to the anti-plasmodial
activity of Ganoderma lucidum extract remains unclear.
Increasing evidence indicates that changes in tissue lipid
content may be implicated in the process [12]. The
present study was aimed at extracting the terpenoid frac-
tion of Ganoderma lucidum fruit body and evaluation of
its potential anti-plasmodial activity when administered
alone or in combination with chloroquine against Plas-
modium beghei in mice.
Materials and methods
Fungal material
Ganoderma lucidum fruit bodies were collected from a
forest reserve at Ipele, Ondo State, Nigeria and botanic-
ally identified by Dr. Soji Fakoya, a mycologist in the De-
partment of Biological Sciences, Joseph Ayo Babalola
University, Ikeji-Arakeji, Nigeria. Specimen sample
assigned voucher number 1103 was deposited in institu-
tion herbarium for reference purpose.
Preparation of ganoderma terpenoid extract (GT)
G. lucidum fruit body thoroughly washed with clean
sterile water was air-dried at room temperature for two
weeks. The dried samples were cut into smaller pieces
and milled into powder using a mechanical grinder. The
terpenoid extraction was carried out according to the
method described by Weng et al. [20] with little modifi-
cations. Briefly, the powdered fungal material (2000 g)
was first extracted by reflux using 50% ethanol for 24 h
at room temperature. The resulting mixture was filtered
using Whatman number 1 filter paper and the combined
filtrate concentrated in vacuo at 35 °C. The concentrated
extract was partitioned between chloroform and water.
The combined chloroform layer was extracted with 5%
NaHCO3 solution. The combined NaHCO3 fraction was
acidified to pH 3 with 2 N HCl under ice-cooling and
then extracted with chloroform. The combined chloro-
form layer was evaporated under reduced pressure to
give a mixture of acidic compounds herein referred to as
Ganoderma terpenoid extract (GT). This was stored in
dark airtight container at 4 °C until used for the
experiment.
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Quantification of total terpenoid content
Total terpene content of the GT extract was quantified
spectrophotometrically based on the method described
by Gao et al. [21] using ganoderic acid A as standard.
The total triterpenoid content was expressed as milli-
grams of ganoderic acid A equivalents per gram of GT.
Animals and treatment
Eighty-four (84) Swiss male mice (between 7 and 9 weeks
old) procured from the animal care facilities of Institute
for Advanced Medical Research and Training (IAM-
RAT), University Teaching Hospital, Ibadan, Nigeria
were used for the study. The animals were kept in stand-
ard mice cages under a controlled environment and with
unrestricted access to food and water. Approval for the
study was granted by Joseph Ayo Babalola University Re-
search and Ethics Committee with approval number
JABU/REC/AS015. All animal experimental procedures
were carried out in strict compliance with the rules
guiding the Care and Use of Laboratory Animals as con-
tained in the National Institutes of Health manual [22].
Parasite inoculation
The malarial parasite Plasmodium berghei (NK-65 strain)
was obtained from the Institute for Advanced Medical Re-
search and Training (IAMRAT), UCH, Ibadan, Nigeria.
Ganoderma terpenoid extract treatment
Two sets of animal experiments were carried out. In the
first experiment intended to ascertain the effect of GT
terpenoid extract alone, 32 male mice were inoculated
intraperitoneally (i.p.) with 0.2 mL 105 P. berghei-in-
fected red blood cells suspended in PBS. Three days
after parasite inoculation, mice in each group were
fasted overnight, weighed and their parasitemia deter-
mined. Thereafter, they were randomly assigned into
four experimental groups (n = 8) designated: CQ, ad-
ministered 30 mg/kg gavage chloroquine—hydroxy-
chloroquine sulfate (Aspen Pharma, Johannesburg,
South Africa); GT100, received 100 mg/kg Ganoderma
terpenoid extract; GT250, received 250 mg/kg Gano-
derma terpenoid extract; INF-CTR, received 1 mL
DMSO. The extract was dissolved in DMSO in order
to keep the concentration and dose similar. Treat-
ment was administered once daily for 12 consecutive
days during which they were observed daily for sur-
vival and their parasitemia level determined every
three days. In another separate experiment, intended
to ascertain the effect of GT extract administered in
combination with CQ,52 male mice were inoculated
intraperitoneally (i.p.) with 0.2 mL 105 P. berghei-in-
fected red blood cells suspended in PBS. Three days
after parasite inoculation, mice in each group were
fasted overnight, weighed and their parasitemia
determined. Thereafter, they were randomly assigned
into four experimental groups (n = 13) designated:
CQ, administered 30 mg/kg gavage chloroquine—
hydroxychloroquine sulfate; GT100 + CQ, received a
combination of 100 mg/kg Ganoderma terpenoid ex-
tract and 30 mg/kg gavage chloroquine—hydroxychlor-
oquine sulfate; GT250 + CQ, received a combination of
250 mg/kg Ganoderma terpenoid extract and 30 mg/
kg gavage chloroquine—hydroxychloroquine sulfate;
INF-CTR, received 1 mL DMSO. Before commence-
ment of the extract treatment, five mice from each
group were sacrificed and their blood samples col-
lected and analyzed to obtain the baseline level of
each parameter monitored. After 12-day treatment,
the animals were fasted overnight, weighed and their
parasitemia estimated from their tail blood samples
before been euthanized and then sacrificed by cervical
dislocation. Upon sacrifice, blood sample was col-
lected from each animal into a plain sample bottles,
liver, kidney, spleen and brain were quickly excise,
blotted on tissue paper, cleared of fats and weighed.
Serum preparation
Blood samples collected in plain tubes were left standing
for 3 h to clot and then centrifuged at 5000 rpm for 10
min at 4 °C. Serum from the centrifuged blood sample
was collected by suction using pasture pipette into ster-
ile plain sample bottles and stored at 4 °C for further
analysis.
Tissue preparation
Liver homogenate was prepared by weighing 2 g of
cleaned tissue and homogenized using 0.1M phosphate
buffer after which it was centrifuged at 5000 rpm (4 °C)
for 10 min to obtain the supernatant which was subse-
quently used as tissue homogenate. Erythrocytes and
liver lipids were extracted with chloroform-methanol
(2:1v/v) according to the method described by Folch
et al. [23].
Biochemical analysis
Erythrocyte and hepatic Phospholipids was estimated
using the procedure described by Stewart [24]. Triglycer-
ide concentration was determined following the protocol
described by Carr et al. [25]. Total cholesterol concen-
tration was estimated according to the method of Allain
et al. [26], and HDL-cholesterol according to Warmick
et al. [27]. LDL-cholesterol was evaluated using Friede-
wald’s equation [28]. Aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) activities were de-
termined using Randox diagnostic kits (Randox Labora-
tory Limited, Antrim, UK).
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Estimation of 3-hydroxy-3-methyl-glutaryl CoA (HMG-
CoA) reductase activities
The ratio of the concentration of 3-hydroxymethyl-glutaryl
CoA (HMG CoA) to mevalonate in the liver was used as a
measure of the activity of HMG-CoA reductase [29].
Statistical analysis
Results are shown as mean ± SEM. Mean of the various
groups were compared by using One-Way Analysis of Vari-
ance (ANOVA) followed by Turkey’s multiple comparisons.
Results with a p < 0.05 were considered significant.
Results
From the 2000 g powdered sample G. lucidum used in
this study, 45.3 g GT was extracted. This translates to
2.27 g GT per 100 gG. lucidum powder. Body weight
change was significantly higher in mice administered
chloroquine alone and chloroquine in combination with
100 mg/kg Ganoderma terpenoid extract compared with
infected untreated mice (Table 1). The observed differ-
ence in body weight change between mice administered
chloroquine and those administered GT at 100 mg/kg
was not significant. The relative liver, kidney, spleen and
brain weights were not significantly different between
mice administered GT (100 and 250mg/kg) compared
to chloroquine (Table 1).
The survival rate of the mice in response to Plasmo-
dium berghei challenge was significantly increased from
66 to 87% due to combined administration of Ganoderma
terpenoid extract at 100mg/kg and CQ compared with
when the same dose of the extract was administered alone
and from 62 to 75% due to administration of the extract at
250mg/kg in combination with CQ compared with when
the extract was administered alone (Fig. 1a and b, respect-
ively). Significant reduction in percentage parasitemia from
21.7 to 10.5% due to combination of Ganoderma extract at
100mg/kg with chloroquine (Fig. 1c and d, respectively).
Erythrocyte triglyceride (Fig. 2a), total cholesterol (Fig. 2b),
LDL-cholesterol (Fig. 2d) and total phospholipid (Fig. 2e)
concentrations were significantly lower in GT +
CQ-treated mice compared to infected but untreated
mice (INF-CTR). No significant alteration was observed
in erythrocyte HDL-cholesterol level between the
treated mice groups and the untreated mice (Fig. 2c). Liver
cholesterol (Fig. 3a) and Phospholipid (Fig. 3b) concentra-
tions were significantly lower in mice administered GT +
CQ compared to infected but untreated mice. 3-Hydroxy-
methylglutaryl-CoA reductase (HMG-CoA reductase) ac-
tivity expressed as a ratio of [HMG-CoA]/[mevalonate]
was significantly higher mice administered Ganoderma
terpenoid extract (100 and 250mg/kg) in combination
with CQ compared to those administered CQ alone and
the infected but untreated mice (Fig. 3c). Serum aspartate
aminotransferase (AST) (Fig. 4a) and alanine aminotrans-
ferase (ALT) (Fig. 4b) activities were significantly lower in
GT + CQ-treated and CQ-treated mice groups compared
to infected but untreated mice.
Discussion
Ganoderma lucidum has been consumed for several
years in countries such as Japan, China and North Korea
due to its many recognized health benefits [30]. In
Nigeria and her neighboring West African states, mush-
room are consumed for their nutritional benefit rather
than for their medicinal values. The component parts of
this mushroom including the mycelium, fruit bodies and
spores have been demonstrated to exhibit different bio-
active properties including antioxidant [15], antitumor
[9], anti-inflammatory [10], antidiabetic [31], antimicro-
bial and antimalarial [12–14] activities, and they are cur-
rently being deployed in the management of diseases
such as cancer hypertension), immunosuppression and
hypercholesterolemia [32]. Based on the positive attri-
butes of mushroom consumption on animal nutrition
and health, increase awareness on the inclusion of
mushroom in our daily meal is warranted. As such, re-
search data demonstrating the potential attributes of
these mushrooms in animal and human studies will go a
long in achieving this set goal.
The 2.27% yield of GT obtained in this study is higher
compared to 1.67% reported by Gao et al. [21]. The
present study, demonstrated the anti-plasmodial activity
of Ganoderma terpenoid extract administered either sin-
gly or in combination with chloroquine in enhancing the
Table 1 Body weight and relative organ weights of Plasmodium berghei-infected mice administered a combination of Ganoderma
terpenoid extract and chloroquine for a period of 12 days
CQ GT100 + CQ GT250 + CQ INF-CTR
Body weight change (g) 12.3 ± 1.2a 10.4 ± 0.7a,b 8.6 ± 0.5b −9.2 ± 0.2c
Relative organ weight
Liver 0.08 ± 0.001a 0.08 ± 0.001a 0.08 ± 0.001a 0.10 ± 0.001b
Kidney 0.03 ± 0.001a 0.03 ± 0.001a 0.03 ± 0.001a 0.04 ± 0.001a
Spleen 0.007 ± 0.001a 0.007 ± 0.001a 0.007 ± 0.001a 0.013 ± 0.001b
Brain 0.03 ± 0.001a 0.03 ± 0.001a 0.03 ± 0.001a 0.03 ± 0.001b
Values are expressed as means ± SEM of 5 or 8 determinations. Values in the same rows carrying different superscript are statistically significant (p < 0.05)
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survival rate of mice infected with P. berghei in addition
to drastically inhibiting the parasite growth and survival
in mice. Significant improvement in body weight ob-
served in the infected mice administered Ganoderma
terpenoid extract in combination with chloroquine fur-
ther attested to the positive health status of the animal.
The efficacy of triterpenes extracted from different fungi
as potential anti-plasmodial agents has been reported by
several authors. In a study by Goulart et al. [33], terpen-
oid related molecules such as farnesol, nerolidol, limon-
ene and linalool were demonstrated to inhibit the
proliferation of P. falciparum in vitro at the intraerythro-
cytic stages. In a similar study, Jordão et al. [34] demon-
strated that nerolidol inhibits the de novo synthesis of
the isoprenic chain attached to the benzoquinone ring
during the intraerythrocytic stages of P. falciparum.
Limonene, a triterpene was also reported to inhibits pro-
tein isoprenylation in the same stages of the parasite
[35]. Halogenated monoterpenes extracted from the
marine red alga, Plocamium cornutum (Plocamiaceae)
exhibited significant anti-plasmodial activity against a
chloroquine-sensitive strain of P. falciparum [36]. Simi-
larly, the eremophilane sesquiterpenoids, berkleasmins A
and C, isolated from Berkleasminum nigroapicale, were
reported to exhibit in vitro antiplasmodial activity with
IC50 values of 6.0 and 5.4 μg, respectively [37]. Lanostanes
isolated from the ethyl acetate extract of Ganoderma luci-
dum was reported to exhibit in vitro anti-plasmodial activ-
ity with IC50 values of between 6 to 20 μM [38]. In a
separate study, garcihombronane D, another lanostane
from Garcinia cymosa (Clusiaceae) showed selective activ-
ity against P. falciparum with IC50 of 7.7 μM) [39].
Results from this study showed that erythrocytes lipids
including triglycerides, cholesterol, LDL-cholesterol and
phospholipid were significantly lower in infected mice
administered Ganoderma terpenoid extract in combin-
ation with chloroquine compared with infected but un-
treated mice. The observation that this trend was not
repeated in mice treated with chloroquine alone seems
to suggest that the this hypolipidemic action could be at-
tributed to Ganoderma terpenoid extract. Several studies
have reported the hypolipidemic activity of different ex-
tracts of Ganoderma species. Oluba et al. [12] had earlier
observed a positive correlation between serum and liver
lipoprotein cholesterol concentration and parasitemia
level in Plasmodium berghei infected mice treated with
aqueous extract of Ganoderma lucidum. The malaria
parasites have a high requirement for cholesterol and
phospholipids for its survival in the human host [40].
Circulating HDL-cholesterol particles and erythrocytic
membrane are the potential sources of cholesterol and
phospholipids for these parasites [40]. Erythrocyte
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Fig. 1 Percentage survival of Plasmodium berghei infected mice administered Ganoderma terpenoid extract (GT) alone (a) and a combination of
GT plus chloroquine (b) with their corresponding parasitemia profile (c) and (d) respectively. Values are means ± SEM of 5 or 8 determinations
Oluba Lipids in Health and Disease           (2019) 18:12 Page 5 of 9
phospholipids content has been demonstrated to in-
crease 500 folds following malarial infection [41]. During
the late stage of the parasite development, infected
erythrocytes contain 3–5 times more phospholipids than
uninfected cells [17]. Vial et al. [42] also reported that
the infected erythrocytes contain phospholipid synthe-
sizing enzymes. Thus, potent inhibitors of plasmodial
phospholipid synthesis was previously characterized as
potential target for anti-malarial chemotherapy due to
its crucial role to the parasite survival [19].
It was also important to evaluate the total cholesterol
and phospholipid contents of the liver because the exo-
erythrocytic stage of the malaria parasite life cycle oc-
curs in the liver. It has been shown that therapeutic
agents targeted at this stage of the parasite life cycle will
go a long way in preventing clinical episodes of malaria.
Results from this study showed that Ganoderma terpen-
oid extract does not only exert its hypolipidemic action
in the erythrocytes but also in the liver. Liver total chol-
esterol and phospholipid contents were significantly re-
duced due to administration of the extract in P. berghei
infected mice. Similar to what obtained in the erythro-
cyte, chloroquine administration does not affect liver
phospholipid and total cholesterol concentrations. Thus,
suggesting that chloroquine may be acting through other
mechanisms other than reduction in hepatic lipids. In
addition, hepatic HMG-CoA reductase, the rate limiting
enzyme in de novo cholesterol synthesis measured as a
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Fig. 2 Erythrocyte triglyceride (a), total cholesterol (b), HDL-cholesterol (c), LDL-cholesterol (d) and phospholipid (e) of Plasmodium berghei
infected mice administered terpenoid extract of Ganoderma lucidum in combination with chloroquine for a period of 12 days. Values are means ±
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ratio of HMG-CoA concentration to mevalonate con-
centration was significantly higher in the extract treated
mice. This is indicative of the fact that the extract in-
hibits the conversion of the substrate, HMG-CoA to
mevalonate by the enzyme HMG-CoA reductase. That is
the extract inhibits hepatic cholesterogenesis. This obser-
vation agrees with the report of Wang et al. [43] who had
earlier demonstrated that lanostane triterpenes isolated
from the fruit bodies of Ganoderma leucocontextum from
Tibet, inhibited HMG-CoA reductase activity in vitro in
rat pig microsomes. In another study, Hajjaj et al. [44] re-
ported that 26-oxygenosterols isolated from G. lucidum
inhibited the enzyme lanosterol 14α-demethylase which
catalyzes the conversion of 24,25-dihydrolanosterol to
cholesterol in human hepatic cell lines.
In order to ascertain the potential toxicity of Gano-
derma terpenoid extract used in this study, serum AST
and ALT activities were measured. Data obtained showed
that mice administered Ganoderma terpenoid extract
had significantly lower AST and ALT activities compared
with untreated control. The enzymes AST and ALT are
membrane-bound enzymes and are routinely used as
biomarkers to estimate the extent of damage to the liver.
Increase levels of this enzymes in the serum or plasma is
indicative of potential damage to hepatic cells thus
bringing about their leakage to the plasma. Thus, high
serum AST and ALT activities are recognized markers of
cellular damage and functional integrity of liver cell
membrane [45, 46]. In the present study, Ganoderma
terpenoid extract was observed to protect the liver
against P. berghei-induced damage. This is demonstrated
in the significant reduction in serum AST and ALT activ-
ities in P. berghei-infected mice treated with the GT ex-
tract. In addition, the relative liver, kidney, spleen and
brain weights of mice treated with the extract was not
different from that obtained for chloroquine-treated
mice. This observation is in agreement with the reports
by several authors. Oluba et al. [12, 14] reported that
crude aqueous and ethanolic extracts of G. lucidum
showed hepatoprotection against P. berghei-infected
mice. Similarly, Wu et al. [47] showed that Ganoderma
triterpenoids demonstrated hepatoprotection against
oxidative damage induced by tert-butyl hydroperoxide in
human hepatic HepG2 cells.
Conclusion
This study demonstrated the antiplasmodial activity of
Ganoderma terpenoid extract through its reduction in
parasitemia and thus improved survival rate in mice in-
fected with P. berghei. It was also demonstrated that
chloroquine potentiates the curative effect of Ganoderma
terpenoid extract on P. berghei in mice. Furthermore,
Ganoderma terpenoid extract exhibited significant hypo-
lipidemic effect through reduction in infected erythrocyte
lipids (triglycerides, total cholesterol, LDL-cholesterol and
phospholipid) and this is suggested as a possible mechan-
ism for its anti-plasmodial activity.
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